M

Memorial Sloan-Kettering Cancer Center | MSK Department of Medicine, Gastrointestinal Research

Research site
(Unclaimed)
Location
300 East 66th Street, New York, New York, United States of America
Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

72 of 1280
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors

A first-in-human study using BDC-1001 as a single agent and in combination with nivolumab in HER2 expressing advanced malignancies

Enrolling
HER2-positive Endometrial Cancer
HER2-positive Colorectal Cancer
Drug: BDC-1001
Drug: Nivolumab

The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to i...

Invitation-only
Waldenstrom Macroglobulinemia
Follicular Lymphoma
Drug: Ibrutinib

A Phase 1 Open-label, Multi-center Study of the Safety, Pharmacokinetics (PK), and Anti-tumor Activity of LYT- 200 in Patients with Relapsed/Refracto...

Enrolling
MDS
AML, Adult Recurrent
Drug: Decitabine
Drug: LYT-200

This is a multi-center, open-label Phase 2 study designed to evaluate the efficacy and safety of BA3021 in PD-1/L1 failure patients with ROR-2 expres...

Enrolling
Metastatic Cancer
Recurrent Squamous Cell Carcinoma of the Head and Neck
Biological: Ozuriftamab Vedotin
Biological: PD-1 inhibitor

This is a global, multicenter, open-label safety extension study. Participants receiving single-agent trastuzumab emtansine or trastuzumab emtansine...

Enrolling
Neoplasm Metastasis
Drug: Trastuzumab
Drug: Pertuzumab

The purpose of this study is to compare the efficacy of JNJ-68284528 (ciltacabtagene autoleucel [cilta-cel]) with standard therapy, either Pomalidomi...

Active, not recruiting
Multiple Myeloma
Drug: Daratumumab
Drug: Bortezomib

This Phase Ib, open-label, multicenter study evaluates the safety, efficacy, and pharmacokinetics of venetoclax in combination with Pola + R-CHP in p...

Active, not recruiting
Lymphoma, Large B-Cell, Diffuse
Drug: Rituximab
Drug: Venetoclax

This study is an open-label, multi-center, dose-escalation, dose expansion study in adult subjects with advanced solid tumors. The study will evaluat...

Active, not recruiting
Non-small Cell Lung Cancer
Castration-resistant Prostate Cancer
Drug: SM08502
Drug: Prednisone

This study has 2 parts. The first part of the study is done. The first part was open to adults with different types of advanced cancer (solid tumors)...

Enrolling
Neoplasms
Drug: BI 907828
Drug: ezabenlimab

This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent...

Enrolling
Abdominal Neoplasm
Neoplasms by Site
Drug: STAR0602

This research study is studying a targeted therapy as a possible treatment for recurrent glioblastoma (GBM).The following intervention will be used i...

Active, not recruiting
Glioblastoma
Procedure: Surgery
Drug: Abemaciclib

This is an open label Phase 1b/2 study to evaluate the efficacy and safety of ACR-368 as monotherapy or in combination with ultralow dose gemcitabine...

Enrolling
Endometrial Adenocarcinoma
Urothelial Carcinoma
Drug: ACR-368
Diagnostic Test: OncoSignature

A Phase I study to evaluate the safety of a novel, orally available, selective, and potent small molecule inhibitor of the histone lysine methyl tran...

Enrolling
Myeloma Multiple
Multiple Myeloma
Drug: KTX-1001

The purpose of this study is to determine if treatment with apalutamide plus androgen deprivation therapy (ADT) before and after radical prostatectom...

Active, not recruiting
Prostatic Neoplasms
Drug: Placebo
Drug: Apalutamide

This is a clinical study for adult patients who have recently been diagnosed with acute myeloid leukemia or AML. AML is a type of cancer. It is when...

Active, not recruiting
Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
Acute Myeloid Leukemia (AML)
Drug: gilteritinib
Drug: azacitidine

The purpose of this study is to compare the efficacy of Bortezomib, Lenalidomide and Dexamethasone (VRd) induction followed by a single administratio...

Enrolling
Multiple Myeloma
Drug: Cyclophosphamide
Drug: Cilta-cel

This is an open-label, dose escalation study to evaluate the safety, toxicity, and pharmacokinetics (PK) as well as preliminary efficacy of BTX-A51 c...

Enrolling
Myelodysplastic Syndrome
Acute Myeloid Leukemia
Drug: Azacitidine
Drug: BTX-A51

The purpose of this study is to compare the efficacy of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Ciltacabtagene Aut...

Enrolling
Multiple Myeloma
Drug: Bortezomib
Drug: Daratumumab

The purpose of this study is to evaluate efficacy of erdafitinib versus chemotherapy or pembrolizumab in participants with advanced urothelial cancer...

Active, not recruiting
Urothelial Cancer
Drug: Erdafitinib
Drug: Vinflunine

The purpose of this study is to evaluate the overall minimal residual disease (MRD) negative rate of participants who receive JNJ-68284528.

Active, not recruiting
Multiple Myeloma
Drug: Lenalidomide
Drug: Daratumumab

Trial conditions

Lymphoma (146 trials)
Leukemia (113 trials)
Prostatic Cancer (105 trials)
Cancer (100 trials)
Breast Cancer (98 trials)
Lung Cancer (85 trials)
Sarcoma (69 trials)
Recurrence (59 trials)
Carcinoma (57 trials)
Central Nervous System C... (50 trials)

And 90 more

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems